calliditas.se (CALT) - Year-over-year earnings per share growth for the last twelve months

calliditas.se - graphic logo of issuer CALT

The quarterly EPS growth trend demonstrates the business's scalability potential: following successful tests, drug production costs remain minimal relative to profits. Strategic alliances are accelerating the expansion of orphan drugs, although integration with Asahi Kasei and pricing controls in the US are creating pressure. The value of 48.70 represents the latest metric reading, helping to assess the fundamental strength of Calliditas Therapeutics (CALT).

Calliditas Therapeutics, Inc. (CALT) - Earnings per share growth in annualized terms for the last twelve months from 07/04/2022 to 09/28/2024

Analytical breakdowns and data insights for company calliditas.se (CALT)

- share price and expert price forecast:
Stock Price Calliditas Therapeutics|CALT - Broker Consensus Forecast
- market capitalization indicators:
Market Value Calliditas Therapeutics, Inc.|CALT - Business Value
- book capitalization data:
Book Value per Share Calliditas Therapeutics|CALT - Total Stockholders' Equity|Market Cap to Net Assets Ratio calliditas.se|CALT - Company Assets
- debt and solvency information:
Total Debt to Capital Calliditas Therapeutics|CALT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Calliditas Therapeutics AB|CALT - Company Aggregate Debts|Debt to Book Capitalization Ratio Calliditas Therapeutics|CALT - Company Long-Term Debt|Company Short-Term Debt Calliditas Therapeutics|Quick Ratio calliditas.se
- earnings and valuation multiples indicators:
CALT - Net Financial Result|Projected Future Earnings Calliditas Therapeutics|CALT - Price to Earnings Multiple|Forward P/E Multiple Calliditas Therapeutics|CALT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Calliditas|CALT - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Calliditas Therapeutics|CALT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months calliditas.se|CALT - Expected net earnings per share growth this year|Expected earnings per share growth for next year Calliditas Therapeutics
- sales volume and revenue indicators:
CALT - Company Sales Revenue|Company Future Sales Volume calliditas.se|CALT - Market Cap to Sales Volume|Forward P/S Multiple Calliditas Therapeutics AB|CALT - Revenue Dynamics YoY (Last Twelve Months)
Initial company analysis:Calliditas Therapeutics
Flagship merchandise of Calliditas Therapeutics

Analyzing net income per share dynamics is critical for selecting assets with a high margin of safety. This indicator measures EPS growth rates following 10-Q filings, allowing for an assessment of Calliditas Therapeutics (CALT) expansion efficiency through partnerships with STADA and Everest Medicines, which is clearly reflected in the quarterly EPS growth figure.

Direct competitors

TVTX: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ARDX|Year-over-year earnings per share growth for the last twelve months ProKidney|Year-over-year earnings per share growth for the last 12 months AKBA (Akebia Therapeutics)|Quarterly EPS earnings growth TVRD|DMAC - Earnings per share growth in annualized terms for the last twelve months|unicycive.com - Year-over-year net earnings per share growth for the last 12 months|Rockwell Medical Inc. (RMTI) - Earnings per share growth in annualized terms for the last twelve months|cadrenal.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months conduitpharma.com|RNLX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months ZyVersa Therapeutics (ZVSA)